Alzheimer's Foundation of America
Select text size: a | a | a
 

Alzheimer's Disease Clinical Trials

Find a Trial

To find a trial, please view the list below. Also visit www.clinicaltrials.gov.

Search by State:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ALABAMA

 

Back to Top

ALASKA

 

Back to Top

ARIZONA

 

Back to Top

ARKANSAS
CALIFORNIA

Location: Long Beach
CNS Network, Inc.

Trial Title and Description:
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease

The purpose of this Phase 2 study is to evaluate how the body handles the drug and the drug's effect on the body of participants with mild cognitive impairment (MCI) due Alzheimer’s Disease (AD) or mild AD who test positive for amyloid plaque.

Enrollment Status: Recruiting

Study Dates: Start: March 2012 Expected Completion: February 2014

Condition: Alzheimer's disease
Age Eligibility: 55 years or older
Gender Eligibility: Male or Female
Enrollment Goal: 129
Clinical Identifier: NCT01561430
Study Phase: Phase 2
Study Type: Interventional

Sponsor: Eli Lilly and Company

Contact Information:
Shelly Asbill
855-425-1515
shellyasbill@cnstrial.com

Back to Top

Location: Long Beach
CNS Network, Inc.

Trial Title and Description:
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext (NOURISH AD)

This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer's Disease.

Enrollment Status: Recruiting

Study Dates: Start: March 2013 Expected Completion: January 2015

Condition: Alzheimer's disease
Age Eligibility: 66-90
Gender Eligibility: Male or Female
Enrollment Goal: 480
Clinical Identifier: NCT01741194
Study Phase: Phase 2/3
Study Type: Interventional

Sponsor: Accera, Inc.

Contact Information:
Shelly Asbill
855-425-1515
shellyasbill@cnstrial.com

Back to Top

Location: Long Beach
CNS Network, Inc.

Trial Title and Description:
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild Alzheimer's Disease.

Enrollment Status: Recruiting

Study Dates: Start: November 2012 Expected Completion: July 2015

Condition: Alzheimer's disease
Age Eligibility: 18-89
Gender Eligibility: Male or Female
Enrollment Goal: 500
Clinical Identifier: NCT01689233
Study Phase: Phase 3
Study Type: Interventional

Sponsor: TauRx Therapeutics Ltd

Contact Information:
Shelly Asbill
855-425-1515
shellyasbill@cnstrial.com

Back to Top

Location: Long Beach
CNS Network, Inc.

Trial Title and Description:
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3) (EPOCH)

The purpose of this study is to assess the efficacy and safety of MK-8931 compared with placebo in the treatment of Alzheimer's Disease (AD). The primary study hypotheses are that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score and that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) score.

Enrollment Status: Recruiting

Study Dates: Start: November 2012 Expected Completion: January 2017

Condition: Alzheimer's disease
Age Eligibility: 55-85
Gender Eligibility: Male or Female
Enrollment Goal: 1960
Clinical Identifier: NCT01739348
Study Phase: Phase 2/3
Study Type: Interventional

Sponsor: Merck

Contact Information:
Shelly Asbill
855-425-1515
shellyasbill@cnstrial.com

Back to Top

Location: Redding, CA

Trial Title and Description: A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication

Enrollment Status: Enrollment Open

Study Dates: Oct 2013 to Jan 2017

Condition: Alzheimer's Disease, Dementia
Age Eligibility: 55-85
Gender Eligibility: Male or Female
Enrollment Goal: 790
Clinical Identifier: NCT01969136
Study Phase: Phase 3
Study Type: Intervention

Sponsor: Forum Pharmaceuticals

Contact Information:
Colleen Penny
Northern California Clinical Research Center
530-247-7049

Back to Top

COLORADO

 

Back to Top

CONNECTICUT

Location:  Institute for Neurodegenerative Disorders – New Haven, CT.

Trial Title and Description:A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease

Enrollment Status: Active

Study Dates:  Nov. 2012 (41 months)

Condition: Alzheimer disease or MCI
Age Eligibility
: 50-90
Gender Eligibility: male and female
Enrollment Goal: 800 subjects
Clinical Identifier
: BAN2401
Study Phase: Phase 2
Study Type: Investigational drug study

Sponsor: Eisai Inc.

Contact Information:
Barbara Fussell RN
800-401-6067
bfussell@indd.org

Back to Top

DISTRICT OF COLUMBIA

Location: Washington, DC
Georgetown University

Trial Title and Description: A Phase 2 multi-center, randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with mild to moderate Alzheimer's (NOBLE)

NOBLE is a clinical study to evaluate an investigational drug for patients with mild to moderate Alzheimer's disease.

Enrollment Status: Enrolling
Study Dates: March 2014 - March 2016
Condition: Alzheimer's Disease
Age Eligibility: 55-85
Gender Eligibility: Both
Enrollment Goal: 450
Clinical Identifier: NCT02079909
Study Phase: Phase 2
Study Type: Interventional

Sponsor: Toyama Chemical Co., Ltd.

Contact Information:
Kelly Behan
(202) 687-0413

Back to Top

Location: Washington, DC
Georgetown University

Trial Title and Description: Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (H8A-MC-LZAZ/ADC-040-A4)
The A4 study is investigating a new drug intervention that may reduce the impact of a protein known as "amyloid" or "beta amyloid" forming plaques in the brain. Scientists believe that the accumulation of amyloid in the brain may play a key role in the eventual development of AD-related memory loss.

Enrollment Status: Enrolling
Study Dates:
Condition: Normal thinking and memory abilities
Age Eligibility: 65-85
Gender Eligibility: Both
Enrollment Goal:
Clinical Identifier:  NCT02008357
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Eli Lilly and Company

Contact Information:
Erica Christian
(202) 687-8800

Back to Top

Location: Washington, DC
Georgetown University

Trial Title and Description: Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) versus Placebo (EXPEDITION 3)
EXPEDITION 3 – a clinical research study looking at an investigational drug for mild Alzheimer's disease.

Enrollment Status: Enrolling
Study Dates: July 2013-December 2016
Condition: Alzheimer's Disease
Age Eligibility: 55 Years to 90 Years
Gender Eligibility: Both
Enrollment Goal: 2100
Clinical Identifier: NCT01900665
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Eli Lilly and Company

Contact Information:
Erica Christian
20-687-8800

Back to Top

Location: Washington, DC
Georgetown University

Trial Title and Description: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease (HarmonyAD)
The HarmonyAD clinical research study is being conducted to determine if an investigational drug given as a pill can safely and effectively reduce the symptoms of agitation and aggression in people with Alzheimer's disease.

Enrollment Status: Enrolling
Study Dates: November 2012-May 2015
Condition: Alzheimer's Disease
Age Eligibility: 50 Years to 95 Years
Gender Eligibility: Both
Enrollment Goal: 400
Clinical Identifier: NCT01735630
Study Phase: Phase 2
Study Type: Interventional

Sponsor: Elan Pharma International Limited

Contact Information:
Erica Christian
(202) 687-8800

Back to Top

Location: Washington, DC
Georgetown University

Merck AD- A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer's Disease (EPOCH)
Currently available medications help manage symptoms but do not slow the course of Alzheimer's disease. Through ongoing clinical research, doctors seek to study new investigational medications that
may control symptoms and, may possibly, help with treatment. We are evaluating the effectiveness and safety of an oral investigational medication that may help slow the progression of mild to moderate
Alzheimer's disease.

Enrollment Status: Enrolling
Study Dates: November 2012 - April 2017
Condition: Alzheimer's Disease
Age Eligibility: 55 Years to 85 Years
Gender Eligibility: Both
Enrollment Goal:1960
Clinical Identifier: NCT01739348
Study Phase: Phase 2 Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp.

Contact Information:
Erica Christian
(202) 687-8800

Back to Top

Location: Washington, DC
Georgetown University

Trial Title and Description: A Novel fMRI biomarker of asymptomatic Alzheimer's disease.

Enrollment Status: Enrolling
Study Dates: September 2014
Condition: Normal cognitive function, Mild Cognitive Impairment, or Alzheimer's Disease
Age Eligibility: 55 years to 85 years
Gender Eligibility: Both
Enrollment Goal: 100
Clinical Identifier: --
Study Phase: --
Study Type:

Sponsor: Alzheimer's Drug Discovery Foundation

Contact Information:
Wesley Horton
(202) 687-9078

Back to Top

FLORIDA

Location: Sunrise

Trial Title and Description: Efficacy and Safety of MK-7622 as Adjunct Therapy to Donepezil in Participants With Alzheimer's Disease (MK-7622-012)

Enrollment Status: Enrolling
Study Dates: Start: October 2013 End: August 2017
Condition: Mild to Moderate Alzheimer's disease
Age Eligibility: 55-85 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 830
Clinical Identifier: NCT01852110
Study Phase: II
Study Type: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Sponsor: Merck
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top


Location: Sunrise

Trial Title and Description: Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients With Mild-Moderate Alzheimer's Disease Treated With Donepezil

Enrollment Status: Enrolling
Study Dates: Start: January 2014 End: January 2016
Condition: Mild to Moderate Alzheimer's Disease
Age Eligibility: 50 years and older
Gender Eligibility: Male/Female
Enrollment Goal: 840
Clinical Identifier: NCT02006641
Study Phase: III
Study Type: Interventional
Sponsor: Lundbeck
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 13

Back to Top


Location: Sunrise

Trial Title and Description: A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication

Enrollment Status: Enrolling
Study Dates: Start: October 2013 End: January 2017
Condition: Mild to Moderate Alzheimer's Disease
Age Eligibility: 55-85 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 790
Clinical Identifier: NCT01969136
Study Phase: III
Study Type: Interventional Allocation: Randomized
Sponsor: EnVivo
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top


Location: Sunrise

Trial Title and Description: A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.

Enrollment Status: Enrolling
Study Dates: Start: June 2012 End: September 2014
Condition: Mild to Moderate Alzheimer's disease with agitation
Age Eligibility: 50-90 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 200
Clinical Identifier: NCT01584440
Study Phase: II
Study Type: Interventional
Sponsor: Avanir
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top


Location: Sunrise

Trial Title and Description: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

Enrollment Status: Enrolling
Study Dates: Start: November 2012 End: December 2013
Condition: Mild to Moderate Alzheimer's with agitation
Age Eligibility: 50-88 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 400
Clinical Identifier: NCT01735630
Study Phase: II
Study Type: Interventional
Sponsor: Elan
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top


Location: Sunrise

Trial Title and Description: A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Enrollment Status: Enrolling
Study Dates: Start: December 2012 End: December 2016
Condition: Mild Cognitive Impairment/Early Alzheimer's disease
Age Eligibility: 50-90 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 800
Clinical Identifier: NCT01767311
Study Phase: II
Study Type: Interventional
Sponsor: Eisai
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top


Location: Sunrise

Trial Title and Description: Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Enrollment Status: Enrolling
Study Dates: Start: July 2013 End: December 2016
Condition: Mild Alzheimer's disease
Age Eligibility: 55-90 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 2100
Clinical Identifier: NCT01900665
Study Phase: III
Study Type: Interventional
Sponsor: Eli Lilly
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top


For more information, connect with the Alzheimer’s Foundation of America’s licensed social workers. Click here or call 866.232.8484. Real People. Real Care.